AWRENCEVILLE, N.J.--(BUSINESS WIRE)--John Fraher, CEO of Adare Pharmaceuticals, a private global pharmaceutical company, has been named Ernst & Young’s Entrepreneur of the Year in the life sciences category in New Jersey. Fraher led the creation of Adare and became CEO in April 2015. He has since grown the company to more than 600 people across four locations, while establishing and directing its vision and success.
The EY Entrepreneur of the Year awards program recognizes entrepreneurs who are excelling in areas such as innovation, financial performance and personal commitment to their businesses and communities. Business leaders were selected for this honor by a panel of independent judges. Finalists for the 2017 award were announced in late April and award winners were recently recognized at a special gala in New Brunswick, New Jersey.
“I am humbled by this honor as it is recognition of all of the hard work we have done to make Adare Pharmaceuticals what it is today,” said John Fraher, CEO of Adare Pharmaceuticals. “Since our founding, we have been inspired to provide product solutions for patients whose needs are not being fully addressed by treatments currently available. This award recognizes what we’ve accomplished thus far and encourages us to continue creating new possibilities for improved patient health.”
Fraher was named CEO of Adare Pharmaceuticals after Aptalis Pharmaceutical Technologies was acquired by TPG in 2015. Prior to being appointed CEO, Fraher was President of Aptalis and also held a number of executive positions at Eurand before it was acquired by TPG and renamed Aptalis. Throughout his career, Fraher has held positions with a number of multinational pharmaceutical companies. He holds a degree in biochemistry from University College in Dublin, Ireland.
As a regional award winner, Fraher is now eligible for consideration for the Entrepreneur of the Year national program. Award winners in several national categories, as well as an overall national winner, will be announced at an awards gala in Palm Springs, California on November 18, 2017.
About Adare Pharmaceuticals
Adare is a high-growth global specialty pharmaceutical company inspired to improve the lives of patients whose treatment needs are not fully addressed by current medications. With a long history of success from concept through commercialization, we use our unique combination of experience, proprietary capabilities and resources to create meaningful products for patients. Our entrepreneurial and performance-driven culture encourages us to take risks, identify promising ideas and see those opportunities through to completion. Our collaborative spirit helps us to develop strong partnerships and provides Adare and our partners with significant advantages in competitive markets. For more information, please visit www.adarepharma.com.
TPG is a leading global alternative asset firm founded in 1992 with more than $73 billion of assets under management and offices in Austin, Beijing, Boston, Dallas, Fort Worth, Hong Kong, Houston, London, Luxembourg, Melbourne, Moscow, Mumbai, New York, San Francisco, Seoul, and Singapore. TPG’s investment platforms are across a wide range of asset classes, including private equity, growth venture, real estate, credit, and public equity. TPG aims to build dynamic products and options for its investors while also instituting discipline and operational excellence across the investment strategy and performance of its portfolio. For more information, visit www.tpg.com.